| Heading: |
Selective Serotonin Reuptake Inhibitors: Packaging |
| Question ID: |
1817276 |
| UIN: |
63299 |
| House: |
Commons |
| Date tabled: |
2025-06-27 |
| Asking Member ID: |
4084 |
| Asking Member display name: |
Esther McVey
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Esther McVey
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, when he plans to publish the report on packaging changes to Selective serotonin reuptake inhibitors, as discussed at the Commission on Human Medicines Antidepressant Risk Minimisation Expert Workin |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-07-04 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
A public assessment report will be published by the Medicines and Healthcare products Regulatory Agency (MHRA) after the completion of the review. The advice of the Commission on Human Medicines (CHM) will be sought after the next meeting of the Antidepre... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |